NeuroPace (NPCE) announced completion of enrollment and implant procedures in its feasibility investigational device exemption, or IDE, study of the RNS System for the treatment of Lennox-Gastaut Syndrome, or LGS, a devastating form of childhood-onset epilepsy characterized by cognitive dysfunction and frequent generalized onset seizures that often lead to injury.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
Questions or Comments about the article? Write to editor@tipranks.com